Építés alatt – nem éles oldal
Belépés
Taking people in Franciaország2. fázis

Exploratory evaluation of the effect of cholestyramine on serum levels of persistent organic pollutants in obese patients

Key facts

Where
Nice, FranciaországSee the site
Phase
2. fázis

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Forrás: 2023-505116-37-00: ki vehet részt

Where in Franciaország

  • Centre Hospitalier Universitaire de NiceNice, FranciaországTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Centre Hospitalier Universitaire De Nice
Trial code
EU 2023-505116-37-00
Record updated
2026. április 27.
Original description
To evaluate the effect of cholestyramine treatment on serum concentrations of different persistent organic pollutants in a population of obese women of childbearing age for whom bariatric surgery is indicatedRead full original descriptionShow less

To evaluate the effect of cholestyramine treatment on serum concentrations of different persistent organic pollutants in a population of obese women of childbearing age for whom bariatric surgery is indicated

Inclusion: Female patients with an accepted indication for bariatric surgery (BMI > 40 kg/m2 or BMI > 35 kg/m2 with complication(s) improveable by surgery); Aged between 18 and 45 years; Having effective contraception (according to Recommendations related to contraception and pregnancy testing in clinical trials Version 1.2 (CTCG Clinical Trials Coordination Group)).

Exclusion: Patients on anti-vitamin K, digoxin, levothyroxine or likely to be on such therapy within 3 months of inclusion; Known allergy or intolerance to cholestyramine; Chronic disease that may interfere with the efficacy of treatment (unbalanced diabetes with HbA1c >7%, known and treated dyslipidaemia, chronic renal failure with GFR <60 ml/min, hepatocellular failure); Pregnant or breastfeeding women; Chronic constipation; Phenylketonuria.

EU CTIS 2023-505116-37-00